PacBio Files for Resale of Shares; Eligible for Proceeds of $14.5M if Warrants are Exercised | GenomeWeb

NEW YORK (GenomeWeb News) – Pacific Biosciences has filed a prospectus for the resale of up to 5.5 million shares of its stock, issuable upon the exercise of warrants.

The Palo Alto, Calif.-based company is not selling any securities under the prospectus, and while it will receive no proceeds from the sale of shares issuable upon exercise of the warrants, it could receive gross proceeds of about $14.5 million if all of the warrants are exercised for cash, PacBio said in its document filed with the US Securities and Exchange Commission on Tuesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: ancient Ethiopian genome indicates greater Eurasian backflow into Africa, sequencing to diagnose cutaneous T cell lymphoma, and more.

The US House of Representatives science committee has passed a bill to require NSF to ensure it only funds projects that are in the national interest.

DuPont teams with genome editing firm Caribou Biosciences for agricultural applications of the technology.

A blogger reviews her experience learning about her gut microbiome by shipping a sample to uBiome.

Sponsored by

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit. 

Sponsored by
Oracle Health Sciences

Brian Wells of Penn Medicine will detail how his team's "PennOmics" integrated healthcare data warehouse accelerates clinical trial recruitment at the point of care, accepts data from wearables, and does it all in a secure, HIPAA- and research-compliant fashion.